Overview: RPR Titre TestIntroduction: The RPR Titre Test measures RPR titre to diagnose syphilis, causing rashes or neurological issues, helping guide antibiotic treatment. Affecting 1 in 2,000 people, syphilis poses diagnostic challenges due to latent stages. Following 2023 Centers for Disease Control and Prevention (CDC) guidelines, it uses agglutination test for high accuracy, supporting bacteriology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in infectious disease.
Other Names: RPR Titre Assay, Syphilis Serology Test.
FDA Status: FDA-approved test, meeting bacteriology standards for diagnostic reliability.
Historical Milestone: RPR testing began in the 1940s with research by Harris, who developed the method. Agglutination advancements in the 1960s improved detection, surpassing earlier Wassermann methods.
Purpose: Measures RPR titre level to diagnose syphilis, guides penicillin therapy, and evaluates patients with rashes, aiming to resolve symptoms.
Test Parameters: RPR titre level
Pretest Condition: No special preparation required. Collect serum. Report history of sexually transmitted infections.
Specimen: Serum (SST, 2-5 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document rashes or neurological issues. Include current medications or sexual history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., neurosyphilis), and sample collection risks.
Procedural Considerations: Uses agglutination test to measure titre, requiring labs with test kits. Results available in 1-2 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or contamination can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Elevated titre suggests syphilis, guiding therapy. Early treatment might prevent complications, while untreated cases lead to death. Negative results may require other tests.
Specialist Consultation: Consult an infectious disease specialist for interpretation.
Additional Supporting Tests: FTA-ABS, VDRL, or PCR to confirm diagnosis.
Test Limitations: Non-specific for stage; correlation with clinical status needed. False positives possible with other conditions.
References: CDC Guidelines, 2023; Journal of Clinical Pathology, Harris A, 2022.
